Ardelyx

ARDX NASDAQ
2.660
-0.080
-2.92%
已收盘, 16:23 06/14 EDT
开盘
2.720
昨收
2.740
最高
2.790
最低
2.640
成交量
4.91万
成交均量(3M)
16.41万
52周最高
4.700
52周最低
1.600
换手率
0.08%
市值
1.67亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Ardelyx ARDX股票价格,Ardelyx股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.
展开 >

最近浏览

名称
价格
涨跌幅